Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$597.42 USD

597.42
69,785

-6.75 (-1.12%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $597.86 +0.44 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Chemed (CHE) Reaches a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.

Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care

by Zacks Equity Research

Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.

Centene (CNC), Pearl Health Unite to Enhance Value-Based Care

by Zacks Equity Research

Centene (CNC) collaborates with Pearl Health to enhance value-based care services for Medicare Advantage members.

Here's Why You Should Add Cigna (CI) Stock to Your Portfolio

by Zacks Equity Research

Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.

Teladoc Health (TDOC) Unveils Solution to Ease Weight Loss

by Zacks Equity Research

Teladoc Health (TDOC) expands weight management capabilities by coming up with a tailored solution that aims to reduce obesity-related medical care expenses for members.

Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SMMV

Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

ADUS vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.

Chemed (CHE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Chemed (CHE) Tops Q4 Earnings Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 5.60% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Q4 Earnings Lag Estimates

by Zacks Equity Research

Amedisys (AMED) delivered earnings and revenue surprises of -9.62% and 1.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.

Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt

by Zacks Equity Research

Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.

The Pennant Group, Inc. (PNTG) Surges 8.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

The Pennant Group, Inc. (PNTG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Up 4.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SMMV